Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.


Search Results to Karl Douglas Lewis

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following items that are connected to Lewis, Karl

Item TypeName
Academic Article Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Academic Article Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Academic Article Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Academic Article Vemurafenib: the road to personalized medicine in melanoma.
Academic Article Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Concept Proto-Oncogene Proteins B-raf
Academic Article Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Academic Article Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Academic Article Impact of depth of response on survival in patients treated with cobimetinib?±?vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Academic Article Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
Academic Article Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib.
Academic Article Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib?±?cobimetinib: a pooled analysis of four clinical trials.
Academic Article Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.
Academic Article Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.

Search Criteria
  • Proto Oncogene Proteins c raf

Copyright © 2023 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)